InflaRx (IFRX) Metrics: History & Chart

InflaRx N.V.(IFRX)

Biotechnology · Jena, TH

$1.61-0.07 (-4.17%)

Delayed quote: Oct 6, 2026, 12:54 PM EDT

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Jena, TH

65 employees

www.inflarx.de

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Niels C. Riedemann

View full financials

Third-Party DCF Estimate (FMP)	$0.20
Price Gap vs Third-Party Estimate	-88.29%

7D Total Return	-7.69%
30D Total Return	-24.32%
YTD Total Return	+66.34%
1Y Total Return	+6.33%
3Y Total Return	-34.88%
5Y Total Return	-31.69%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+66.34%
2025	-59.11%
2024	+51.53%
2023	-47.42%
2022	-34.87%
2021	-5.37%
2020

CAGR TTM	+6.30%
CAGR 3Y	-13.32%
CAGR 5Y	-7.34%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

IFRX Valuation Metrics

IFRX Stock Price Metrics

IFRX Dividend Metrics

IFRX Growth Rate Metrics

IFRX Discounted Cash Flow Metrics

IFRX Returns By Period

IFRX Yearly Returns

IFRX Average Annual Returns By Period (CAGR)

IFRX Revenue Metrics

IFRX PE Ratio Metrics

IFRX PS Ratio Metrics

IFRX PB Ratio Metrics

IFRX Price to Free Cash Flow Ratio Metrics

IFRX Debt to Equity Ratio Metrics

IFRX PEG Ratio Metrics

IFRX FCF Yield

IFRX Earnings Yield

IFRX EBITDA Yield

IFRX OCF Yield

IFRX EV/EBIT Ratio Metrics

IFRX EV/EBITDA Ratio Metrics

IFRX EV/Assets Ratio Metrics

IFRX EV/Sales Ratio Metrics

IFRX Current Ratio Metrics

IFRX Quick Ratio Metrics

IFRX ROIC Metrics

IFRX Return on Assets Metrics

IFRX Return on Equity Metrics

IFRX Net Profit Margin Metrics

IFRX Gross Profit Margin Metrics

IFRX Tax Rate Metrics

PS Ratio	3595.43
PS Ratio Avg TTM	1866.99
PS Ratio Avg 3Y	869.65
Current VS TTM Avg	+92.58%
Current VS 3Y Avg	+313.43%
Current VS 5Y Avg	+313.43%

PB Ratio	1.18
PB Ratio Avg TTM	1.95
PB Ratio Avg 3Y	1.14
Current VS TTM Avg	-39.52%
Current VS 3Y Avg	+3.70%
Current VS 5Y Avg	+0.93%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.02
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	-65.04%
Current VS 3Y Avg	-46.59%
Current VS 5Y Avg	-53.73%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.16
Ev/Assets Ratio Avg TTM	1.18
Ev/Assets Ratio Avg 3Y	0.67
Current VS TTM Avg	-86.42%
Current VS 3Y Avg	-76.28%
Current VS 5Y Avg	-77.63%

Ev/Sales Ratio	3121.54
Ev/Sales Ratio Avg TTM	1627.36
Ev/Sales Ratio Avg 3Y	670.96
Current VS TTM Avg	+91.82%
Current VS 3Y Avg	+365.23%
Current VS 5Y Avg	+365.23%

Current Ratio	8.22
Current Ratio Avg TTM	4.79
Current Ratio Avg 3Y	6.99
Current VS TTM Avg	+71.66%
Current VS 3Y Avg	+17.58%
Current VS 5Y Avg	+7.08%

Quick Ratio	8.22
Quick Ratio Avg TTM	4.67
Quick Ratio Avg 3Y	5.91
Current VS TTM Avg	+75.90%
Current VS 3Y Avg	+39.06%
Current VS 5Y Avg	+11.78%

ROIC	(25.38%)
ROIC Avg 3Y	(68.73%)
ROIC Avg 5Y	(58.07%)
Current VS 3Y Avg	+63.08%
Current VS 5Y Avg	+56.31%
Current VS 10Y Avg	+43.17%

ROA	(23.88%)
ROA Avg TTM	(15.11%)
ROA Avg 3Y	(12.52%)
Current VS TTM Avg	-58.06%
Current VS 3Y Avg	-90.70%
Current VS 5Y Avg	-115.46%

ROE	(27.27%)
ROE Avg TTM	(82.96%)
ROE Avg 3Y	(64.82%)
Current VS TTM Avg	+67.13%
Current VS 3Y Avg	+57.93%
Current VS 5Y Avg	+50.49%

Net Profit Margin	(155582.08%)
Net Profit Margin Avg TTM	(11329.47%)
Net Profit Margin Avg 3Y	(10979.33%)
Current VS TTM Avg	-1273.25%
Current VS 3Y Avg	-1317.04%
Current VS 5Y Avg	-4291.17%

Gross Profit Margin	(24677.94%)
Gross Pft Margin Avg TTM	1706.35%
Gross Pft Margin Avg 3Y	(71.79%)
Current VS TTM Avg	-1546.24%
Current VS 3Y Avg	-34275.95%
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A